Brainstorm Cell Therapeutics Inc.

And welcome to the Brainstorm Cell Therapeutics first quarter 2023 earnings call. At this time, participants are in a listen-only mode. As a reminder, this call is being recorded. I would now like to introduce your host for today's call, Michael Wood of LifeSite Advisors. Mr. Wood, you may begin.

Good morning, and thank you for joining us. Earlier today, Brainstorm issued a press release with its financial results for the first quarter of 2023, including a corporate update. Before passing it over to the company management for prepared remarks, I want to remind listeners that this conference call will contain numerous statements, descriptions, forecasts, and projections regarding Brainstorm Cell Therapeutics and its potential future business operations and performance, statements regarding the market potential for the treatment of neurodegenerative diseases such as ALS, of the company's existing capital resources for continuing operations in 2023 and beyond, safety and clinical effectiveness of the neuron technology platform, clinical trials of neuron and related clinical development programs, and the company's ability to develop strategic collaborations and partnerships to support its business planning efforts. Forward-looking statements are subject to numerous risks and uncertainties, many of which are beyond Brainstorm's control, including the risks and uncertainties described time to time in the company's SEC filings. The company's results may differ materially from those projected on today's call, and the company undertakes no obligation to publicly update any forward-looking statements. Joining us on the call this morning will be Hein Leibowitz, President and CEO of Brainstorm, Dr. Stacey Lindberg, Co-Chief Executive Officer, and Ella Patlis, Interim Chief Financial Officer. In addition, the company's Executive VP and Chief Medical Officer, Dr. Kirk Taylor, is also on the call and will be available to answer your questions during the Q&A session. So with that, I would like to turn the call over to Mr. Leibowitz.

Please go ahead. Thank you, Michael.